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   The predictive value of grade, number of tumor and histology of mucosal biopsy for tu-
mor recurrence, the course of carcinoma in situ and microinvasion of carcinoma in situ were 
examined. The Kaplan-Meier's method was used for the estimation of the recurrence-free 
rate in the patients who had undergone transurethral resection (TUR) and the logrank test 
for testing the significance of difference in recurrence-free rate. 
   The 5-year ecurrence-free rate was 32.2%. The recurrence-free rate was 51.0 % after 40 
months postoperatively in patients with a single tumor, 12.8% after 42 months postoperatively 
in those with multiple tumors. The patients with a single tumor had a significantly higher 
recurrence-free rate than those with multiple tumors (P<0.001). The recurrence-free rate was 
analyzed according to the grade of main tumor, but significant difference was not present 
   The recurrence-free rate was 44.4% after 42 months postoperatively in patients with 
normal histology of mucosal biopsy and 9.5% after 34 months postoperatively in those with 
abnormal histology. The patients showing normal histology in mucosal biopsy had a signi-
ficantly higher recurrence-free rate than those with abnormal findings (P<0.001). 
   The recurrence-free rate at the same area of biopsy site was analyzed according to the 
histologies of 537 mucosal biopsies. The recurrence-free rate was 76.7% after 42 months po-
st operatively in areas with a normal biopsy, 44.3% after 35 months postoperatively in those 
with abnormal histology and the difference was statistically significant (P'(0.001). 
   Of the 15 patients found to have carcinoma in situ, 4 were primary carcinoma in situ, 
6 were associated with superficial papillary tumors and 5 were associated with invasive tumors. 
Thirteen of the 15 patients were alive and free of disease 18 to 42 months later. Two patients 
associated with invasive tumor died 5 and 18 months after transcatheter embolization of in-
ternal iliac arteries. Of the 13 patients who were found to have microinvasion of carcinoma 
in situ, 4 were not associated with visible tumor, 6 were associated with superficial papillary
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tumor and 3 were associated with invasive tumors. Nine of the 13 patients are alive and free 
of disease 7 to 53 months later. A patient without any visible tumor who was treated with 
TUR and intravesical chemotherapy died and three patients with invasive tumor died irres-
pective of the mode of treatment. 
   As a result of these observations the recurrence of bladder cancer is a manifestation of 
a field change in urothelium remaining after the removal of visible lesions. The information 
obtained by multiple mucosal biopsis is valuable in determining the forms of management 
in patients with bladder cancer and may have predictive value. We have regarded the presence 
of widespread carcinoma in situ and mici oinvasion of carcinoma in situ as indicating a poor 
prognosis and feel that the treatment of choice is a radical cystectomy for patients with 
these lesions as much as possible.
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緒 言
膀胱癌症例に対する腫瘍部以外の膀胱粘膜多部位生














































主腫瘍の組織学的異型度がG2の 症例 におい ても
治療の多 くがTUR.で,TUR後 に放射線療法を併
用 した2例 は,主 腫瘍が浸潤性でTUR後 に筋層に
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内癌の微小浸潤が認められた4例 の うち1例 は後に膀
胱全摘除術を施行したが,残 り3例は全身状態不良な

























































































ではTURに 術後抗癌剤の膀胱腔 内注入 を併用 した
1例は術後13ヵ月 目に癌死 し,膀胱全摘除術施行の3
例は観察期間は短いが再発の徴候な く生存 している.

































































































ついては臨床的意義が不明確な為 これ らが主 要な
組織学的所見の症例は検討 よ り除外 した.主 腫瘍の


























































































































































































上皮内癌の分類については,原 発性上皮 内癌 と可
視的腫蕩を伴った上皮内癌とに分け た もの15,16),こ













































対する初回治療はTURが5例,膀 胱全摘 除術 施行





























































皮内癌のうち,初 回治療としてTURを 行な い,後









た2例 は死亡 し,残 り13例は再発の徴候なく生存中で
ある.しか し経過観察期間は最長でも42ヵ月であるか
ら,今後の長期追跡が必要 と考えられる.





































































































































































動物膀胱への移植 に よって示され54-56>,臨床的 に
はTUR時 に発生するhotgasによって熱傷 を受
けやす く,かつ腫瘍細胞の集塊が気泡 に付着 して表
面張力で保持される頂部A7・49),および膀 胱鏡,切 除
鏡,カテーテルなどの先端 で傷 害を受 けやす い後
壁などに再発腫瘍の発生 頻度が高 い こと,さ らに
TUR-Btと同時にTUR-Pを施行 した症例では前立





















































除術19回,その他3回 となるが,主踵 瘍 の組 織学的
















































法1例で,こ のうちA型でTURと 抗癌 剤の膀胱 膣
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